Lyell Immunopharma (LYEL) Return on Sales (2021 - 2023)
Historic Return on Sales for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 2265.8%.
- Lyell Immunopharma's Return on Sales fell 9558000.0% to 2265.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 7989.83%, marking a year-over-year decrease of 49599200.0%. This contributed to the annual value of 5486.67% for FY2024, which is 37670200.0% down from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Return on Sales is 2265.8%, which was down 9558000.0% from 5483.0% recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Return on Sales registered a high of 0.23% during Q4 2022, and its lowest value of 21395.33% during Q3 2022.
- For the 5-year period, Lyell Immunopharma's Return on Sales averaged around 4480.9%, with its median value being 2097.24% (2023).
- Per our database at Business Quant, Lyell Immunopharma's Return on Sales crashed by -213775900bps in 2022 and then skyrocketed by 192980900bps in 2023.
- Quarter analysis of 5 years shows Lyell Immunopharma's Return on Sales stood at 16.73% in 2021, then soared by 99bps to 0.23% in 2022, then plummeted by -1721920bps to 4032.62% in 2023, then crashed by -342bps to 17838.82% in 2024, then soared by 87bps to 2265.8% in 2025.
- Its Return on Sales stands at 2265.8% for Q3 2025, versus 5483.0% for Q2 2025 and 7643.57% for Q1 2025.